Vericel (NASDAQ:VCEL) Posts Quarterly Earnings Results

Vericel (NASDAQ:VCEL) issued its earnings results on Thursday. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08, FiscalAI reports. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The firm had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.69 million. During the same period in the previous year, the company posted ($0.01) earnings per share. The business’s revenue was up 22.5% on a year-over-year basis.

Here are the key takeaways from Vericel’s conference call:

• Record Q2 revenue of $77.5 million increased 22% year over year, driven by strength in both MACI and Burn Care. GAAP net income reached $2.2 million and free cash flow was $14.3 million.
• Vericel raised full-year 2026 revenue guidance to $330 million–$340 million, including higher MACI guidance of $284 million–$290 million and Burn Care guidance of $46 million–$50 million. Management cited strong biopsy and implant growth, commercial execution, and continued MACI Arthro adoption.
• Burn Care revenue rose 22% to approximately $12 million, with Epicel contributing $10.4 million and NexoBrid reaching record revenue of more than $1.5 million. NexoBrid also posted records for ordering centers and hospital unit sales, while BARDA procurement is expected to contribute approximately $3 million in Q3.
• The board authorized Vericel’s first $200 million share repurchase program, supported by approximately $227 million in cash and investments. Management said the program will be balanced with continued investment in internal growth, international expansion, clinical studies, and potential M&A.
• Vericel submitted a U.K. marketing authorization application for MACI and remains on track for a potential 2027 launch, while the MACI ankle MASCOT study began enrolling patients. Management expects the U.K. opportunity to require only a limited commercial investment, but approval and reimbursement remain pending.

Vericel Stock Up 2.1%

Shares of NASDAQ:VCEL traded up $0.99 during midday trading on Thursday, reaching $47.61. 986,900 shares of the company traded hands, compared to its average volume of 467,569. Vericel has a 12 month low of $28.95 and a 12 month high of $49.32. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 113.36 and a beta of 1.07. The firm’s fifty day moving average price is $41.73 and its two-hundred day moving average price is $37.33.

Wall Street Analysts Forecast Growth

VCEL has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Vericel in a report on Tuesday. Weiss Ratings upgraded shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Truist Financial boosted their price target on shares of Vericel from $42.00 to $54.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a research note on Thursday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $57.50.

Insider Buying and Selling

In other news, insider Sean C. Flynn sold 15,000 shares of the company’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $40.21, for a total transaction of $603,150.00. Following the sale, the insider directly owned 1,647 shares in the company, valued at $66,225.87. This represents a 90.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jonathan Siegal sold 2,732 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $44.90, for a total transaction of $122,666.80. Following the completion of the sale, the insider directly owned 886 shares in the company, valued at approximately $39,781.40. The trade was a 75.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 47,732 shares of company stock worth $2,084,167 in the last 90 days. 7.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vericel

Hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. increased its holdings in Vericel by 13.7% during the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 353 shares during the period. California State Teachers Retirement System grew its position in shares of Vericel by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock valued at $1,932,000 after purchasing an additional 382 shares in the last quarter. Commonwealth Equity Services LLC grew its position in shares of Vericel by 3.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 11,698 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 410 shares in the last quarter. MML Investors Services LLC increased its holdings in shares of Vericel by 6.0% in the fourth quarter. MML Investors Services LLC now owns 10,217 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 579 shares during the period. Finally, Kestra Advisory Services LLC bought a new position in shares of Vericel in the fourth quarter worth $27,000.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.